Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Menu

    Xanamem

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actinogen secures FDA Agreement to Advance Xanamem for Alzheimer
    Actinogen secures FDA Agreement to Advance Xanamem for Alzheimer

    15 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/15/3149989/0/en/Actinogen-achieves-agreement-with-the-FDA-in-a-Type-C-meeting-on-the-manufacturing-clinical-and-nonclinical-activities-required-for-a-future-US-marketing-approval-of-Xanamem-for-Al.html

    GLOBENEWSWIRE
    15 Sep 2025
    Share Share
    Huadong Medicine Reports Positive Phase I Results For GLP-1 Agonist HDM1002
    Huadong Medicine Reports Positive Phase I Results For GLP-1 Agonist HDM1002

    26 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/huadong-medicine-announces-positive-phase-i-results-for-innovative-oral-small-molecule-glp-1-receptor-agonist-hdm1002-302183199.html

    PR NEWSWIRE
    26 Jun 2024
    Share Share